Abstract
A longitudinal in vivo study has been completed to evaluate the angiogenic benefit of an adenoviral vector used to express vascular endothelial growth factor (VEGF 165). Subsequently, numerous methods of therapeutic angiogenesis, including different gene delivery vehicles as well as the route of administration of these vectors, have been studied using angiographic time-intensity data. Mathematical modeling of these data provides indices of the formation and function of new vessel growth in response to the treatment modality. The angiographic and immunohistological results demonstrate that adenoviral (Ad) delivery of VEGF promotes a rapid angiogenic effect within the first week of treatment. However, this effect is not sustained and returns to control levels within three weeks. These results support the conclusion that Ad mediated therapeutic angiogenesis may not provide long term benefit.
| Original language | English |
|---|---|
| Title of host publication | Proceedings of the 2005 Summer Bioengineering Conference |
| Pages | 709-710 |
| Number of pages | 2 |
| Volume | 2005 |
| State | Published - Dec 1 2005 |
| Event | 2005 Summer Bioengineering Conference - Vail, CO, United States Duration: Jun 22 2005 → Jun 26 2005 |
Other
| Other | 2005 Summer Bioengineering Conference |
|---|---|
| Country | United States |
| City | Vail, CO |
| Period | 6/22/05 → 6/26/05 |
Fingerprint
ASJC Scopus subject areas
- Engineering(all)
Cite this
Adenoviral delivery of vegf promotes short term angiogenic effect. / Gounis, Matthew J.; Lieber, Baruch B.; Webster, Keith A; Spiga, M. Grazia; Bishopric, Nanette; Wakhloo, Ajay K.
Proceedings of the 2005 Summer Bioengineering Conference. Vol. 2005 2005. p. 709-710.Research output: Chapter in Book/Report/Conference proceeding › Conference contribution
}
TY - GEN
T1 - Adenoviral delivery of vegf promotes short term angiogenic effect
AU - Gounis, Matthew J.
AU - Lieber, Baruch B.
AU - Webster, Keith A
AU - Spiga, M. Grazia
AU - Bishopric, Nanette
AU - Wakhloo, Ajay K.
PY - 2005/12/1
Y1 - 2005/12/1
N2 - A longitudinal in vivo study has been completed to evaluate the angiogenic benefit of an adenoviral vector used to express vascular endothelial growth factor (VEGF 165). Subsequently, numerous methods of therapeutic angiogenesis, including different gene delivery vehicles as well as the route of administration of these vectors, have been studied using angiographic time-intensity data. Mathematical modeling of these data provides indices of the formation and function of new vessel growth in response to the treatment modality. The angiographic and immunohistological results demonstrate that adenoviral (Ad) delivery of VEGF promotes a rapid angiogenic effect within the first week of treatment. However, this effect is not sustained and returns to control levels within three weeks. These results support the conclusion that Ad mediated therapeutic angiogenesis may not provide long term benefit.
AB - A longitudinal in vivo study has been completed to evaluate the angiogenic benefit of an adenoviral vector used to express vascular endothelial growth factor (VEGF 165). Subsequently, numerous methods of therapeutic angiogenesis, including different gene delivery vehicles as well as the route of administration of these vectors, have been studied using angiographic time-intensity data. Mathematical modeling of these data provides indices of the formation and function of new vessel growth in response to the treatment modality. The angiographic and immunohistological results demonstrate that adenoviral (Ad) delivery of VEGF promotes a rapid angiogenic effect within the first week of treatment. However, this effect is not sustained and returns to control levels within three weeks. These results support the conclusion that Ad mediated therapeutic angiogenesis may not provide long term benefit.
UR - http://www.scopus.com/inward/record.url?scp=33646582615&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33646582615&partnerID=8YFLogxK
M3 - Conference contribution
AN - SCOPUS:33646582615
SN - 0974249211
SN - 9780974249216
VL - 2005
SP - 709
EP - 710
BT - Proceedings of the 2005 Summer Bioengineering Conference
ER -